Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Related Studies

Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This study is ongoing, but not recruiting participants.

Study NCT00079378. Last updated on July 29, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia
		Lymphoma

2	Additional conditions recognized in this trial
		Leukemia, B-Cell
		Leukemia, Lymphocytic, Chronic, B-Cell
		Leukemia, Lymphoid
		Leukemia, Myeloid
		Leukemia, Myeloid, Acute

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		decitabine
		valproic acid

5	More general drug interventions related to this trial
		Anticonvulsants
		Antimanic Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Central Nervous System Agents
		Central Nervous System Depressants
		Enzyme Inhibitors
		GABA Agents
		Molecular Mechanisms of Pharmacological Action
		Neurotransmitter Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Psychotropic Drugs
		Therapeutic Uses
		Tranquilizing Agents

6	Sponsors listed in this trial
		Arthur G. James Cancer Hospital &Richard J. Solove Research Institute
		National Cancer Institute (NCI)